SCHEMBL3975209

SCHEMBL3975209

CCN(CC)c1c(C)cc(C)c(NC(=O)c2sccc2NS(=O)(=O)c2ccccc2)c1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYTH2 Q99418 1/20 0.41
ACLY P53396 1/20 0.41
TSHR P16473 3/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 1/20 0.40
METAP2 P50579 3/20 0.40
FFAR4 Q5NUL3 1/20 0.40
EDNRA P25101 5/20 0.40
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
MAPT P10636 1/20 0.39
GAA P10253 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 1/20 0.39
NRP1 O14786 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975224 0.85 CYTH2 (0.43) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL3971801 0.84 ACLY (0.45) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL533542 0.83 FFAR4 (0.57) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL3973395 0.83 ACLY (0.44) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL3981381 0.83 LMNA (0.48) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL532871 0.82 MEN1 (0.45) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL3981841 0.82 EDNRA (0.41) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL3976237 0.81 MEN1 (0.44) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL3975743 0.80 KDM4E (0.41) CYTH2ACLYTSHRLMNAHPGD
SCHEMBL3972606 0.80 MAPK1 (0.42) LMNAEDNRAKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579340-B2 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists PFIZER INC (US) 2009-08-25 US claimed
US-20070293503-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS, INC. 2007-12-20 US claimed
US-7288538-B2 Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation ENCYSIVE PHARMACEUTICALS, INC. (US) 2007-10-30 US claimed
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-03 US claimed
US-7579340-B2 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists PFIZER INC (US) 2009-08-25 US disclosed
US-20070293503-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS, INC. 2007-12-20 US disclosed
US-7288538-B2 Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation ENCYSIVE PHARMACEUTICALS, INC. (US) 2007-10-30 US disclosed
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 CYTH2 187/4885ACLY 4820/4885TSHR 1741/4885
US-20070293503-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 CYTH2 187/4885ACLY 4820/4885TSHR 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.